Trial Profile
Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tuberculosis vaccine (Primary) ; Antibacterials
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 19 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 19 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jul 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.